Remifentanil/Sufentanil for CABG+/-AVR Evaluated by Recovery, Cognitive Function, Haemodynamics and Biochemical Markers. (PRECON2)

Aarhus University Hospital

Status and phase

Completed

Phase 4

Conditions

Aortic Stenosis

Ischaemic Heart Disease

Treatments

Drug: Sufentanil

Drug: Remifentanil

Study type

Interventional

Funder types

Other

Identifiers

NCT02053818

2010-022428-58

Details and patient eligibility

About

To evaluate the effect on cognitive function, recovery, cardioprotection and haemodynamics of standard Remifentanil anaesthesia to standard Sufentanil anaesthesia in patients undergoing coronary artery bypass with or without aortic valve replacement.

Full description

Haemodynamic effects, evaluated by invasive haemodynamic data (arterial line and PAC) of opioid given as single drug and in combination with Propofol (first 30 patients only).
Cognitive dysfunction evaluated by standard test preoperative and postoperative day 1, 4 and 30
Recovery quality and time parameters using objective ICU score criteria
Cardioprotection effect evaluated by myocardial biochemical markers obtained preoperative and postoperative 4, 9 and 18 hours

Enrollment

60 patients

Sex

All

Ages

60 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients scheduled for coronary artery bypass grafting (CABG) +/- aortic valve replacement (AVR)

Exclusion criteria

Ejection Fraction < 30%
Previous Myocardial Infarction within 4 weeks
Severe pulmonary hypertension (mean pulmonary artery pressure (mPAP) > 33% of mean arterial pressure (MAP)
Arterial hypertension (Sap > 180, Dap > 110)
Diabetes, Non- and Insulin dependent
Non usable echocardiography windows